nct_id: NCT07054190
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2025-07-08'
study_start_date: '2025-09-09'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Ribociclib'
  - drug_name: 'Drug: Inavolisib'
  - drug_name: 'Drug: Letrozole'
long_title: A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy
  of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated,
  Early-stage, PIK3CA-Mutated Breast Cancer
last_updated: '2025-11-12'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE2
principal_investigator: NA
principal_investigator_institution: Hoffmann-La Roche
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 60
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Histologically confirmed operable or inoperable invasive Stage II-III BC according
  to American Joint Committee on Cancer (AJCC) TNM staging classification'
- '* Candidate for neoadjuvant treatment and considered appropriate for endocrine
  combination therapy'
- '* Willingness to undergo breast surgery (mastectomy or breast-conserving surgery)
  after neoadjuvant treatment (unless inoperable)'
- '* Documented ER-positive tumor in accordance with current American Society of Clinical
  Oncology (ASCO)/College of American Pathologists (CAP) guidelines'
- '* Documented HER2-negative tumor in accordance with current ASCO/CAP guidelines'
- '* Documented Ki-67 score \>=5% as per local assessment'
- '* Confirmed PIK3CA mutation'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Stage IV (metastatic) BC
- Exclude - * Inflammatory BC (cT4d)
- Exclude - * Bilateral invasive BC
- Exclude - * History of ductal carcinoma in situ or lobular carcinoma in situ if
  they have received any systemic therapy for treatment or radiation therapy to the
  ipsilateral breast
- Exclude - * Previous systemic or local treatment for the primary BC currently under
  investigation (including excisional biopsy or any other surgery of the primary tumor
  and/or axillary lymph nodes, including sentinel lymph node biopsy, radiotherapy,
  cytotoxic, and endocrine treatments)
- Exclude - * Type 2 diabetes requiring ongoing systemic treatment at the time of
  study entry; or any history of Type 1 diabetes
short_title: A Study to Test Inavolisib Treatments in Participants With Early-Stage,
  PIK3CA-Mutated Breast Cancer
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Hoffmann-La Roche
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This study will evaluate the safety and efficacy of inavolisib combination
  therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen
  receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative
  breast cancer (BC).
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Arm A
      arm_internal_id: 0
      arm_description: Participants will receive inavolisib and letrozole orally (PO)
        once a day (QD) from Day 1 to 28 and ribociclib PO QD from Day 1 to 21 in
        cycles 1-5 (each cycle=28 days). In cycle 6, inavolisib, ribociclib and letrozole
        will be administered PO QD on days 1-21 (each cycle=21 days).
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Inavolisib'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Ribociclib'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Letrozole'
        level_internal_id: 2
        level_suspended: N
    - arm_code: Arm B
      arm_internal_id: 1
      arm_description: 'Participants will receive a starting regimen of inavolisib
        and letrozole PO QD from Day 1 to 28 in cycle 1 (each cycle=28 days). Starting
        on Day 1 of Cycle 2, all participants will receive the triplet regimen inavolisib
        + ribociclib + letrozole as follows: inavolisib and letrozole PO QD from Day
        1 to 28 and ribociclib PO QD from Day 1 to 21 in cycles 2-5 (each cycle=28
        days). In cycle 6, inavolisib, ribociclib and letrozole will be administered
        PO QD on days 1-21 (each cycle=21 days).'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Inavolisib'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Ribociclib'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Letrozole'
        level_internal_id: 2
        level_suspended: N
    - arm_code: Arm C
      arm_internal_id: 2
      arm_description: 'Participants will receive a starting regimen of ribociclib
        PO QD from Day 1 to 21 and letrozole PO QD from Day 1 to 28 in cycle 1 (each
        cycle=28 days). Starting on Day 1 of Cycle 2, all participants will receive
        the triplet regimen inavolisib + ribociclib + letrozole as follows: inavolisib
        and letrozole PO QD from Day 1 to 28 and ribociclib PO QD from Day 1 to 21
        in cycles 2-5 (each cycle=28 days). In cycle 6, inavolisib, ribociclib and
        letrozole will be administered PO QD on days 1-21 (each cycle=21 days).'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Inavolisib'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Ribociclib'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Letrozole'
        level_internal_id: 2
        level_suspended: N
    match:
    - and:
      - and:
        - or:
          - clinical:
              oncotree_primary_diagnosis: Breast Ductal Carcinoma In Situ
          - clinical:
              oncotree_primary_diagnosis: Invasive Breast Carcinoma
          - clinical:
              oncotree_primary_diagnosis: Breast Lobular Carcinoma In Situ
          - clinical:
              oncotree_primary_diagnosis: Breast Neoplasm, NOS
          - clinical:
              oncotree_primary_diagnosis: Inflammatory Breast Cancer
        - clinical:
            age_numerical: '>=18'
            gender: Female
            her2_status: Negative
            er_status: Positive
            disease_status:
            - Advanced
      - or:
        - genomic:
            hugo_symbol: PIK3CA
            variant_category: Mutation
